Public company, workplace, funding, and market signals
Updated Aug 16, 2026
Ro is a privately held, direct-to-patient healthcare company founded in 2017. It combines nationwide telehealth, clinical services, diagnostics/labs, pharmacy fulfillment, and ongoing care through its vertically integrated Ro Operating System (ro.OS). Its major current focus is digitally delivered care for weight management, sexual health, hair loss, dermatology, fertility, and related health goals.
Primary product
Ro’s vertically integrated direct-to-patient healthcare platform, including Ro Body for weight management, telehealth visits, provider messaging, diagnostics, pharmacy fulfillment, insurance support, and ongoing care.
Founded
2017
Headquarters
625 6th Ave, New York, NY 10011, United States
Team size
600-700
Work style
Hybrid
Industry
Hospitals and Health Care
Sub-industry
Digital health, telehealth, direct-to-patient healthcare, and online pharmacy
Offices
Business model
Stage
Private, late-stage venture / Series D
Total raised
$1B
Latest round
Series D extension / additional financing · Feb 2022
Latest amount
$150M
Series D extension / additional financing
Feb 2022 · ShawSpring Partners
Mar 2021 · General Catalyst, FirstMark Capital, and TQ Ventures
Jul 2020 · General Catalyst
Apr 2019
Sep 2018
Aug 2017 · General Catalyst
Leadership
Co-Founder & Chief Executive Officer
Co-Founder & Chief Product Officer
Melynda Barnes, MD
Chief Medical Officer
Todd Levy
Chief Technology Officer
Aron Susman
Chief Financial Officer
Founders
Co-Founder; formerly Chief Growth Officer
Ro describes its culture as strongly performance-driven but compassionate, or “Big Heart.” It emphasizes metrics-driven work, patient-first decision-making, ownership, strong attract/strong repel cultural fit, deep technical and clinical collaboration, and preference for the best idea regardless of title or tenure. New York-area employees are generally expected in the office Tuesdays and Thursdays, while employees elsewhere in the U.S. can work remotely with periodic in-person collaboration.
Work style
Hybrid
Compensation
Ro publicly advertises equity for full-time employees and a broad benefits package. Public job postings reviewed did not provide sufficiently consistent salary ranges to report a reliable company-wide compensation benchmark.
Benefits
Pricing
Cash-pay membership plus separately billed medication and, where applicable, laboratory services. Ro Body pricing publicly lists $39 for the first month, then approximately $74-$149 per month depending on prepaid or monthly plan; medication is generally not included in the membership fee. Ro also supports insurance-covered medication options.
Differentiators
Technology
Customers
Competitors
Estimated revenue
Approximately $200M-$600M annually based on conflicting third-party estimates; one company-profile data source reports approximately $257M, while Sacra estimated approximately $598M of annualized revenue for 2024. These are estimates, not company-reported financial statements.
Estimated monthly visits
8.2M
Traffic estimate as of Jun 2026
Ro reduced its workforce by approximately 18% to manage expenses, improve organizational efficiency, and align resources with its strategy. The reduction followed a $150 million financing and a $7 billion reported valuation earlier in 2022.
SourceCo-founder and Chief Growth Officer Rob Schutz stepped back from his operating role and moved into an advisory position shortly after the workforce reduction. Other senior departures reported in the same period included COO George Koveos and Ro Pharmacy GM Steve Buck.
SourceRo acquired Modern Fertility to expand its women’s-health and reproductive-health capabilities. The transaction was reported by TechCrunch as valued at more than $225 million, although Ro’s announcement did not disclose a price.
SourceRo acquired Kit, an at-home diagnostics company with CLIA-certified laboratory infrastructure, to expand testing and preventative-care capabilities.
SourceRo acquired Workpath, an API platform for on-demand in-home care and diagnostic services.
SourceRo · Jan 2026
Ro announced a nationwide integration for Novo Nordisk’s Wegovy pill, positioning Ro as a launch and access channel for the oral GLP-1 medication.
Ro · Apr 2025
Ro announced integration with NovoCare Pharmacy, offering eligible patients access to FDA-approved Wegovy at a stated $499 monthly cash price.
Ro · Dec 2024
Ro announced an integration with LillyDirect to make Zepbound single-dose vials available through Ro-affiliated providers and Lilly’s self-pay pharmacy channel.
TechCrunch · Oct 2024
CEO Zachariah Reitano discussed Ro’s private-company status and the company’s strategic focus on GLP-1 weight-loss care.
Ro · May 2024
Ro formally introduced ro.OS, its proprietary platform integrating telehealth, laboratory, pharmacy, provider, and patient-care workflows.
53 jobs at Ro